What is Therapeutics?
Therapeutics Inc. operates as a specialized dermatology Contract Research Organization (CRO), providing integrated, turnkey solutions that span the entire drug development lifecycle. By navigating the intricate landscape of non-clinical, clinical, and regulatory processes, the firm acts as a vital partner for pharmaceutical entities seeking to bring dermatological innovations to market. With a legacy spanning over two decades, the company leverages deep domain expertise to streamline product development and regulatory affairs, ensuring that complex clinical workflows are managed with precision and transparency. Their market position is defined by a focus on collaborative drug development, which facilitates seamless communication between stakeholders and regulatory bodies, ultimately accelerating the path to approval for essential dermatological therapies.
How much funding has Therapeutics raised?
Therapeutics has raised a total of $2.3M across 2 funding rounds:
Debt
$1M
Debt
$1.3M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.3M led by PPP
Key Investors in Therapeutics
PPP
Public-Private Partnership
What's next for Therapeutics?
With the recent infusion of capital, Therapeutics Inc. is well-positioned to scale its enterprise-level operations and further refine its proprietary drug development frameworks. The strategic focus will likely shift toward enhancing digital integration within their clinical trial management systems and expanding their regulatory consulting footprint to address emerging global compliance standards. By leveraging this financial backing, the company aims to solidify its leadership in the dermatology CRO space, potentially exploring new therapeutic modalities or expanding its geographic reach to support a broader portfolio of international clients. The emphasis remains on maintaining high-quality, turnkey service delivery while navigating the evolving complexities of the global pharmaceutical regulatory environment.
See full Therapeutics company page
